Last reviewed · How we verify
NCT05348928
A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System - A Non-Significant Risk Study
trial testing Continuous glucose monitoring device in Continuous Glucose Monitoring in 16 participants. Completed in 16 June 2022.
16 June 2022
Quick facts
| Lead sponsor | Sinocare Meditech Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 4 May 2022 |
| Primary completion | 16 June 2022 |
| Estimated completion | 16 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Continuous glucose monitoring device
- Laboratory plasma glucose concentration determination
Conditions studied
- Continuous Glucose Monitoring — all drugs for Continuous Glucose Monitoring →
Sponsor
Sinocare Meditech Inc.
Who can join
Adults 18 to 65, any sex, with Continuous Glucose Monitoring. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the investigation is to obtain sufficient preliminary information about the performance of the TrueVie Continuous Glucose Monitoring (CGM) device to identify any need for any design modifications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05348928
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Continuous glucose monitoring device
Trials testing the same drug.
- NCT05806554 — Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial · completed
- NCT05537480 — Correlation of CGM Metrics With OGTT and Pregnancy Outcomes in Pregnant Women With or Without a High Risk for GDM · NA · unknown
- NCT04825366 — Restoration of Hypoglycemia Awareness With Home-based High Intensity Interval Training · NA · completed
- NCT03295578 — Blood Glucose, Cognition and Wellbeing @ Work · NA · completed
Other recruiting trials for Continuous Glucose Monitoring
Currently open trials in the same condition.
- NCT07097415 — The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Type 2 Diabetes · NA · recruiting
- NCT06648174 — The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus · NA · recruiting
- NCT06641765 — Continuous Glucose Monitoring in Dialysis Patients With Diabetes · NA · active not recruiting
- NCT06716671 — Influence of Continuous Glucose Monitoring on Quality of Life in People With Type 2 Diabetes Mellitus · active not recruiting
- NCT06436326 — The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05348928 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinocare Meditech Inc.
- Last refreshed: 30 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05348928.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing